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ADVERSE HEALTH EFFECTS OF PCBs:
INTERPRETING THE EPIDEMIOLOGICAL EVIDENCE
Philippe Grandjean
Department of Environmental Medicine, University of Southern Denmark, 5000 Odense,
Denmark; and Department of Environmental Health, Harvard School of Public Health,
P.O.Box 15697, Boston, MA 02215, USA
Introduction
Although polychlorinated biphenyls (PCBs) have been in use for 75 years and dioxin / furan
contamination has been known for several decades, current knowledge on their adverse impacts on
human health is limited. For example, the U.S. EPA’s risk assessment for noncarci ogenic effects
of PCBs is based on animal studies carried out with industrial Aroclor products. Their congener
compositions substantially differ from the weathered mixture that humans are exposed to. A recent
critique has focused on the validity of epidemiological findings. Thus, the American Council on
Science and Health concluded:1 ‘…there is no conclusive evidence that background PCB levels in
the general population, or even the very high levels to which some occupational groups were
exposed, have resulted in acute effects, increased cancer risk, “endocrine disruption”, or
widespread intellectual deterioration in children exposed to PCBs in utero.’
Such controversy should inspire an assessment of the weaknesses associated with observational
studies of PCB-exposed populations. Interpretation should take into account what can be
reasonably demonstrated by such studies. These considerations may lead to improved study
designs, and prudent decisions on preventive efforts should involve a cautious evaluation of the
epidemiological data. This paper addresses some key issues in regard to exposure assessment, the
temporal association between exposure and suspected outcomes, the possible impact of
concomitant exposures, and the choice of appropriate outcome variables.
Exposure Assessment
Ideally, the exposure estimate should reflect the concentration of toxic agents at the vulnerable
target.  The main concern of the analytical chemist is to optimize the analytical quality, i.e., both
precision and accuracy. While this issue is crucial, the validity of the results when applied in an
epidemiological study must also consider specimen characteristics, e.g., whether a blood sample
was taken from fasting subjects, or whether the sample reflects the maternal or the f tal
circulation. Fortunately, when the result is expressed on a lipid basis, PCB concentrations are
similar in maternal and cord serum (Figure 1, left). However, the correlation shows more scatter
when one sample is assessed on a wet-weight basis (Figure 1, right).
Modern congener-specific analyses also allow determination of the non-rtho-chlorinated and
mono-ortho-chlorinated PCBs that are associated with dioxin-like effects.2 However, within a
population with dietary exposure to PCBs from the same sources, the concentrations of different
congeners generally show a very high degree of association with one another.3 Thus, the total PCB
concentration, which is mainly based on persistent di-ortho substituted PCBs, correlates very well
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with the estimated weighted concentration of dioxin-equivalent concentrations of mono-ortho-
substituted PCBs (Figure 2, left). Thus, such epidemiological studies are unlikely to enable
separation of effects that may be attributed to individual PCBs or PCB congener groups.
Figure 1. Total PCB concentration in paired samples of (left) maternal serum and cord serum
(open squares) and maternal transitional milk (closed circles) (N = 18), and (right) in
whole-blood (lipid-based) from the cord and in the cord tissue (wet weight) (N = 50). The
total PCB concentration was calculated as the sum of congeners CB-138, CB-153, and
CB-180 multiplied by 2.0. Serum and whole-blood concentrations are expressed in
relation to the lipid content, while the cord tissue concentration is on a wet-weight basis
due to the low lipid content that makes lipid assessment unreliable. The correlation
coefficients were 0.97 for maternal and cord serum, 0.94 for maternal serum and milk
(left), and 0.83 for cord blood and cord tissue (right). Two different laboratories analyzed
cord tissue (open squares and filled circles), and a third analyzed cord blood. Data are
from Faroese Cohorts 2 (left) and 1 (right).4,5
Temporal Connection between Exposure and Outcomes
The exposure estimate should also be representative in regard to the suspected time of toxic
damage. Because weathered PCB congeners are generally highly persistent, a serum obtained
today will probably show almost the same PCB concentration as one obtained last year. However,
this assumption is true only if the subject maintained his or her body weight and did not
substantially change dietary habits. In regard to studies of developmental toxicity, greater changes
may occur due to the impact of postnatal exposure from breast-feeding. Thus, although a child is
born with a PCB body burden similar to the mother’s (Figure 1, left), the resulting serum-PCB
concentration of the child after completion of the breast-feeding period may be different (Figure 2,
right). If the child has not been breast-fed, the increased body size will result in a dilution of the
PCB concentration in the body, while prolonged breast-feeding can lead to levels that exceed those
of the mother. Such differences may allow epidemiological studies to determine the relative
impact of prenatal and postnatal exposures.6
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Interpreting exposure estimates in regard to time windows of vulnerability is of course of key
importance in developmental toxicity studies. However, its relevance to cancer studies has not
been properly emphasized. Thus, most studies of PCB-associated cancer have determined the
subjects’ exposure from a serum or tissue sample obtained at the time of diagnosis or up to a few
years before. Not surprisingly, most of these studies have failed to document a significant effect of
the serum PCB concentration. The absence of statistical significance may be due to exposure
misclassification and does not necessarily indicate a lack of an effect.
Figure 2. Total and dioxin-equivalent weighted mono-ortho PCB concentrations in maternal serum
(N = 119) (left) and total PCB concentrations in maternal pregnancy serum and the
child’s serum at 18 months of age (N = 116) (right).  The total PCB concentration was
calculated as the sum of congeners CB-138, CB-153, and CB-180 multiplied by 2.0,
while the concentrations mono-ortho congeners CB-105, CB-118, and CB-156 were
added after multiplication by the dioxin toxicity equivalency factors.2 All con entrations
are expressed in relation to the lipid content. The correlation coefficients were 0.96 for
analyses of maternal serum, and 0.53 for PCB in maternal and child serum samples.  Data
are from Faroese Cohort 3.7
In most cases, exposure imprecision is likely non-differential, i.e., the coefficient of variation will
be independent of the level of exposure.  Such misclassification will lead to an underestimation of
its true association with the outcomes. The dose-effect or dose-response relationships then become
biased toward the null hypothesis: The greater the imprecision, the larger the bias. In addition,
adjustment for confounders may further dilute the dose-association with the outcome. Sensitivity
analysis may provide adjustment for the effects of the exposure misclassification, but it requires
that the imprecision is known. Due to toxicokinetic factors and other preanalytical variation,
laboratory reproducibility alone will substantially underestimate the total imprecision of PCB
exposure biomarkers. Thus, if laboratory imprecision is used for such adjustment, the association
with outcome parameters will remain biased.
Organohalogen Compounds, Volumes 60-65, Dioxin 2003 Boston, MA
0.1
1
10
100
1 10 100
Cord blood mercury (µg/L)
M
a
te
rn
a
l 
se
ru
m
 P
C
B
 (
µ
g
/g
 l
ip
id
)
Concomitant Exposures
PCBs occur in the environment with other lip philic and persistent pollutants. As with correlations
between PCB congeners themselves, other contaminant concentrations are often closely associated
with those of the PCBs. However, the contaminant profile will vary geographically, it will depend
on the trophic level of the diet, and will change with time. In human studies, much attention has
been paid to chlorinated dibenzo-p dioxins and associated furans, chlorinated pesticides, and
methylmercury. Concomitant exposure to such compounds can increase the apparent PCB-
associated risk, unless adjustment for the concomitant exposures is carried out. However, if the
concomitant exposures are highly associated with PCB, this confounding is difficult to resolve.
Figure 3. Total PCB concentration in maternal pregnancy serum and the mercury concentration in
cord blood (N = 182).  The total PCB concentration was calculated as in Figure 1. The
correlation coefficient was 0.43. Data are from Faroese Cohort 2.4
In some cases, adjustment for this confounding effect is possible; e.g., in regard to methylmercury
when the association between mercury and PCB concentrations is not close (Figure 3). In a study
of Faroese birth cohort 1, the neuropsychological test results suggested PCB-associated deficits.5
However, this association disappeared when adjusted for the mercury exposure level. On the other
hand, when the children were separated into three groups according to the mercury exposure
tertiles, a PCB effect appeared most clearly in the group with the highest concomitant
methylmercury exposures.5
Outcome Indicators
Effect parameters must be chosen with careful attention to the a pri ri hypotheses. An insensitive
outcome test may lead to underestimation of the true effect, and non-specific effect measures are
often subject to confounding. Among additional considerations, all tests should be appropriate for
the age and culture, they should be conducted by highly skilled professional examiners and should
employ feasible, modern technology.
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Figure 4. Total PCB concentration in serum collected from Faroese Cohort 2 children at age 54
months in regard to the most recently assessed body weight (at 42 months). The body
weight has been adjusted for sex, birth weight, and maternal smoking during pregnancy,
while the serum-PCB concentration has been adjusted to an average p nderal ind x.6
The PCB-associated adverse effects that have attracted most attention are postnatal growth,
neurobehavioral development, immune function, and cancer. One complication in human studies
of postnatal growth is that breast-fed children in general show smaller increases in height and
weight as compared to children who are bottle-fed. Although the extent of this effect appears to
vary for unknown reasons, the significance of PCB exposure from breast-milk has only recently
been determined. A prospective study of the Faroese Cohort 2 replicated the inverse association of
body weight and height with duration of breast-feeding, but this effect was fully accounted for by
the calculated amounts of methylmercury or PCB transferred to the infant through human milk.6 In
addition, the confounder-adjusted body weight at 42 months was negatively associated with the
child’s PCB concentration in the serum (obtained with a delay of 12 months) (Fig. 4).
The available evidence documents that subtle neurobehavioral effects may occur as a result of both
prenatal PCB exposure and transfer via breast-milk.8 Although immunotoxic effects provide the
basis for the U.S.EPA’s evaluation of non-carcinogenic risks due to PCB exposure, too little is
known about effects in humans on clinically relevant immunological parameters. While previous
studies have suggested some adverse effects, increasing evidence now indicates that antibody
responses to childhood vaccinations may be adversely affected by developmental PCB exposures.7
This new information may very well lead to lower exposure limits.
Conclusions
Epidemiological studies are crucial to risk assessment, but offer only incomplete insight due to the
limitations of observational studies, which depend, e.g., on study opportunities. Often the follow-
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up is too short, or the exposure estimates do not reflect the long induction time of the health
outcomes under study. These problems tend to cause an underestimation of the true effects caused
by PCBs. On the other hand, confounding from concomitant exposures to other toxic substances
may be difficult to control for and may therefore cause an overestimation of the effects. Due to the
high correlation of PCB congeners, such population studies are unlikely to reflect toxicity
differences between congeners. Still, the associations found appropriately reflect the prevalent
exposures to pollutant mixtures, where PCBs constitute a major part.
In designing future studies, populations should be identified, where exposures cover a wide
interval and are only weakly related to socioeconomic and other confounders. Preferably, more
than one exposure variable should be obtained, and they should reflect the time period of greatest
relevance for the outcome variables chosen. Because of high correlations between congener
concentrations, analytical efforts should focus on the most prevalent lipophilic co aminants,
while detailed population exposure profiles may be characterized from analysis of pool samples.
Joint studies or meta-analyses of comparable cohorts may enable comparison of outcomes related
to different exposure profiles. Although the potential effects have been insufficiently studied so
far, accumulating evidence suggests that clinically important deficits in neurobehavioral and
immune function may occur at widely prevalent exposure levels.
While more insight is being gathered, prudent prevention should be based on cautious
interpretation of the available documentation, rather than a harsh and unfounded critique like the
one quoted in the Introduction. The absence of statistically significant associations by no means
indicates that an effect is not present. Emphasis should be placed on confidence intervals rather
than p values. In addition, the likely underestimation due to imprecise exposure assessment and
insensitive outcome variables should be taken into account. Because the PCBs are highly
persistent, the exposures will remain and will continue to provide challenges to risk assessment.
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